# Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model

> **NCT05507567** · PHASE2 · COMPLETED · sponsor: **Pneumagen Ltd.** · enrollment: 104 (actual)

## Conditions studied

- Influenza Viral Infections

## Interventions

- **DRUG:** Neumifil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05507567
- **Lead sponsor:** Pneumagen Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-12
- **Primary completion:** 2023-05-04
- **Final completion:** 2023-05-04
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05507567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05507567, "Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05507567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*